M. Kobayashi

发表

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.

Derek Y. Chiang, S. Gabriel, T. Golub, 2009, Cancer research.

Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of Gastroenterology.

Serial changes in liver stiffness and controlled attenuation parameter following direct‐acting antiviral therapy against hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Prolonged hepatitis after acute infection with genotype H hepatitis B virus.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Internal medicine.

Response to long‐term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Virological differences between patients infected with subtypes Ba and Bj of hepatitis B virus genotype B

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Journal of gastroenterology and hepatology.

Deletions in the hepatitis B virus core gene may influence the clinical outcome in hepatitis B e antigen–positive asymptomatic healthy carriers

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998, Journal of medical virology.

Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus

K. Chayama, Yoshiyuki Suzuki, M. Kobayashi, 2012, Journal of Gastroenterology.

Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Digestive Diseases and Sciences.

Correlation between hepatitis B virus surface antigen level and alpha‐fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of medical virology.

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, H. Kumada, 2013, Journal of medical virology.

Prediction of Treatment Efficacy and Telaprevir-Resistant Variants after Triple Therapy in Patients Infected with Hepatitis C Virus Genotype 1

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of Clinical Microbiology.

Infection Treatment of Hepatitis C Virus Genotype 1 Variants for Prediction of Efficacy of Utility of Detection of Telaprevir-Resistant

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013 .

Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon‐alpha‐2b and ribavirin in hepatitis C patients

Yoshiyuki Suzuki, H. Tsuda, M. Kobayashi, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Emergence of telaprevir‐resistant variants detected by ultra‐deep sequencing after triple therapy in patients infected with HCV genotype 1

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of medical virology.

Long‐term interferon monotherapy reduces the risk of HCV‐associated hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Amino Acid Substitutions in the Hepatitis C Virus Core Region and Lipid Metabolism Are Associated with Hepatocarcinogenesis in Nonresponders to Interferon plus Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Intervirology.

Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non‐responders infected with HCV genotype 1

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2011, Intervirology.

Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2010, Hepatology.

Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 2a High Viral Load and Virological Response to Interferon-Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

A matched case‐controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of medical virology.

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP‐424), pegylated interferon and ribavirin for 12 weeks

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Internal medicine.

Virological and Biochemical Features in Elderly HCV Patients with Hepatocellular Carcinoma: Amino Acid Substitutions in HCV Core Region as Predictor of Mortality after First Treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

The Efficacy of 24-Week Interferon Monotherapy for Type C Liver Cirrhosis in Japanese Patients with Genotype 1b and Low Virus Load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Intervirology.

Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Predictive factors of virological non‐response to interferon–ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare‐up

N. Hiraga, Yoshiyuki Suzuki, M. Kobayashi, 2005, Journal of medical virology.

Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype2a low viral load and response to interferon monotherapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of medical virology.

Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining region

K. Chayama, H. Handa, Yoshiyuki Suzuki, 1999, Journal of medical virology.

Epidemiology, treatment and health economics of Hepatitis C in Japan (Review)

I. Kamae, P. McEwan, M. Kobayashi, 2014 .

Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of Gastroenterology.

Efficacy of Lamivudine Therapy and Factors Associated with Emergence of Resistance in Chronic Hepatitis B Virus Infection in Japan

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Intervirology.

Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Digestive Diseases and Sciences.

Efficacy of Interferon Therapy in Elderly Patients with Chronic Hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Intervirology.

Origin of neovascular structure in an early stage of hepatocellular carcinoma: Study of alpha‐smooth muscle actin immunohistochemistry in serial thin sections of surgically resected cancer

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of gastroenterology and hepatology.

Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Gut and liver.

Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Hepatology International.

Correlation of Histopathological Features andGenetic Variations with Prognosis of JapanesePatients with Nonalcoholic Fatty Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016 .

SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Internal medicine.

Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Intervirology.

Usefulness of serum KL-6 for early diagnosis of idiopathic pulmonary fibrosis in patients with hepatitis C virus.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, The American journal of medicine.

Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of medical virology.

Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver

Yoshiyuki Suzuki, K. Kinowaki, T. Fujii, 2019, Internal medicine.

Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report

Yoshiyuki Suzuki, Y. Torisu, M. Kobayashi, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Scandinavian journal of gastroenterology.

Clinicopathological improvement of non‐alcoholic steatohepatitis associated with weight loss during a 14‐year follow‐up period

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Liver international : official journal of the International Association for the Study of the Liver.

Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of gastroenterology and hepatology.

Heterogeneous type 4 enhancement of hepatocellular carcinoma on dynamic CT is associated with tumor recurrence after radiofrequency ablation.

M. Kobayashi, K. Ikeda, H. Kumada, 2011, AJR. American journal of roentgenology.

New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Influence of the reference scan and scan time on the arterial phase of liver magnetic resonance imaging

M. Kobayashi, S. Saitoh, Tatsuya Hayashi, 2018, Radiological Physics and Technology.

Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2022, Oncology.

Usefulness of the Serum KL-6 Assay in Patients with Hepatitis C Virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998, Cancer.

Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, World journal of gastroenterology.

Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment

J. Shindoh, Yoshiyuki Suzuki, I. Yasuda, 2021, Internal medicine.

Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2022, Journal of Gastrointestinal Surgery.

Clinicopathological indices to predict hepatocellular carcinoma molecular classification

Bin Zhang, M. Mahajan, Y. Hoshida, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Virological and Biochemical Relapse after Discontinuation of Lamivudine Monotherapy for Chronic Hepatitis B in Japan: Comparison with Breakthrough Hepatitis during Long-Term Treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Histological Improvements after a Three-Year Lamivudine Therapy in Patients with Chronic Hepatitis B in Whom YMDD Mutants Did Not or Did Develop

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Intervirology.

Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2008, Journal of Gastroenterology.

Long-Term Outcome after Interferon Therapy in Elderly Patients with Chronic Hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Intervirology.

Relationship between pretreatment viremia level and response to interferon-α therapy in chronic hepatitis c differs in viral type 1 and 2 infections

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1996, Digestive Diseases and Sciences.

Pathogenic Significance and Organic Virus Levels in Patients Infected with TT Virus

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Intervirology.

Time course of histological changes in patients with a sustained biochemical and virological response to corticosteroid withdrawal therapy for chronic hepatitis B

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, American Journal of Gastroenterology.

HBcrAg is a predictor of post‐treatment recurrence of hepatocellular carcinoma during antiviral therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Liver international : official journal of the International Association for the Study of the Liver.

Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of Clinical Microbiology.

Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all‐oral direct‐acting antiviral regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Oncology.

Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Journal of Clinical Microbiology.

Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of Gastroenterology.

Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, The American journal of medicine.

Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease

J. Marrero, K. Chayama, Quanzhen Li, 2022, Science Translational Medicine.

Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: Long‐term follow up of a pilot study

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Journal of gastroenterology and hepatology.

Prolonged‐efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease

T. Miyati, T. Fujii, M. Kobayashi, 2017, Gut and liver.

The useful predictors of zinc deficiency for the management of chronic liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2022, Journal of Gastroenterology.

No‐touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Magnetic resonance laparoscopy: A new non‐invasive technique for the assessment of chronic viral liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Potential of laparoscopy in chronic liver disease with hepatitis B and C viruses

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Relationship of angiographic finding with neovascular structure detected by immunohistochemical staining of α‐smooth muscle actin in small hepatocellular carcinoma

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998, Journal of gastroenterology and hepatology.

PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, BMC Gastroenterology.

Endoscopic Regression and Evaluation of Injection Sclerotherapy for Esophageal Varices in Case of Hepatocellular Carcinoma with Portal Vein Invasion.

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1996 .

Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Internal medicine.

Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Internal medicine.

Prolonged‐interferon therapy reduces hepatocarcinogenesis in aged‐patients with chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: Multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Scandinavian journal of gastroenterology.

Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Oncology.

Effects of a sodium‐glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Hepatology communications.

Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, BMC Gastroenterology.

Potential of a no‐touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intrasubsegmental recurrence of small and single hepatocellular carcinomas

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non‐alcoholic fatty liver disease complicated by diabetes mellitus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, BMC Gastroenterology.

Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2022, Hepatology communications.

Circulating MicroRNA‐122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology communications.

Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, BMC Gastroenterology.

The Lack of Hepatocyte Steatosis in Adult-onset Type II Citrullinemia Patients as Assessed by 7-year Interval Paired Biopsies

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2019, Internal medicine.

Impact of sodium-glucose co-transporter 2 inhibitor for non-alcoholic fatty liver disease complicated by diabetes mellitus -Prospective study based on the serial liver biopsy-

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016 .

Therapeutic effects of short‐ and intermediate‐term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Serum levels of γ-globulin and total bilirubin influence the prevalence of multiple extrahepatic complication in patients with hepatitis C virus infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003 .

Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2022, Journal of Gastrointestinal Surgery.

Evolution of simeprevir‐resistant variants in virological non‐responders infected with HCV genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Journal of medical virology.

Effectiveness and safety of reduced‐dose telaprevir‐based triple therapy in chronic hepatitis C patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Evolution of simeprevir‐resistant variants over time by ultra‐deep sequencing in HCV genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of medical virology.

Utility of Detection of Telaprevir-Resistant Variants for Prediction of Efficacy of Treatment of Hepatitis C Virus Genotype 1 Infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of Clinical Microbiology.

Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology.

Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Efficacy of reduction therapy of natural human β‐interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of reduction therapy of natural human β‐interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and Anticarcinogenic Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated Cirrhosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Intervirology.

Three-Dimensional Imaging Using Contrast-Enhanced and Three-Dimensional Ultrasound Techniques in the Ablative Zone Treated with a Multipolar Radiofrequency Ablation System for Hepatocellular Carcinoma

M. Kobayashi, K. Ikeda, H. Kumada, 2016, Oncology.

New ablation procedure for a radiofrequency liver tissue coagulation system using an expandable needle

K. Ikeda, M. Kobayashi, H. Kumada, 2007, Liver international : official journal of the International Association for the Study of the Liver.

Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Influence of Hepatitis C Virus Subtype on Hepatocellular Carcinogenesis: A Multivariate Analysis of a Retrospective Cohort of 593 Patients with Cirrhosis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Intervirology.

Early viral kinetics and treatment outcome in combination of high‐dose interferon induction vs. pegylated interferon plus ribavirin for naïve patients infected with hepatitis C virus of genotype 1b and high viral load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Journal of medical virology.

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

Arthur Liberzon, Masahiro Kobayashi, Yujin Hoshida, 2011, Gastroenterology.

Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Journal of Gastroenterology.

Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Journal of Gastroenterology.

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Internal medicine.

Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Internal medicine.

Hepatitis B Virus-Related Hepatocellular Carcinogenesis and Its Prevention

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Consistently Low Hepatitis B Virus DNA Saves Patients from Hepatocellular Carcinogenesis in HBV-Related Cirrhosis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Intervirology.

Relationship of hepatocellular carcinogenesis with precore mutant virus and serum hepatitis B virus DNA concentration: A longitudinal analysis of patients with cirrhosis

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998 .

High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Journal of Gastroenterology.

Estimating the cost‐effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b

I. Kamae, P. McEwan, M. Kobayashi, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

A case of drug-induced acute liver failure caused by corticosteroids

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2022, Clinical Journal of Gastroenterology.

Real‐world effects of long‐term rifaximin treatment for Japanese patients with hepatic encephalopathy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of hepatology.

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of hepatology.

The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of hepatology.

Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of hepatology.

Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct‐acting antivirals regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Journal of medical virology.

Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha‐fetoprotein in patients without hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

Hepatitis C virus subtype 3b infection in a hospital in Japan: Epidemiological study

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1996, Journal of Gastroenterology.

Effect of Acute Self-Limited Hepatitis C Virus (HCV) Superinfection on Hepatitis B Virus (HBV)-Related Cirrhosis. Virological Features of HBV–HCV Dual Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Digestive Diseases and Sciences.

Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of hepatology.

Usefulness of hepatitis C virus RNA counts by second generation HCV bDNA-probe in chronic hepatitis C based on the HCV genotype

K. Chayama, A. Tsubota, Y. Suzuki, 1998, Journal of Gastroenterology.

Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of gastroenterology and hepatology.

Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B

Yoshiyuki Suzuki, Mio Tanaka, M. Kobayashi, 2014, Journal of Gastroenterology.

Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

M. Kudo, S. Kaneko, A. Zhu, 2018 .

Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of Clinical Virology.

Hepatic vascular side effects of styrene maleic acid neocarzinostatin in the treatment of hepatocellular carcinoma

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Enzyme-linked immunosorbent assay to detect hepatitis C virus serological groups 1 to 6

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, Journal of Gastroenterology.

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Oncology.

Virological Response and Hepatocarcinogenesis in Lamivudine-Resistant Hepatitis B Virus Genotype C Patients Treated with Lamivudine plus Adefovir Dipivoxil

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

Long-Term Follow-Up of HBeAg-Positive Young Adult Japanese Patients Treated with Corticosteroid Withdrawal Therapy for Chronic Hepatitis B

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Intervirology.

Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Progressive and sufficient decrease of hepatitis B core antibody can predict the disappearance of hepatitis B virus DNA in Japanese patients with hepatitis B surface antigen clearance

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2021, Oncology.

Peripheral CD8+/CD25+ lymphocytes may be implicated in hepatocellular injuries in patients with acute-onset autoimmune hepatitis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus‐related liver cancer

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of Gastroenterology.

Influence of HMG-CoA reductase inhibitor to virological response of peginterferon/ribavirin combination therapy in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008 .

Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b.

I. Kamae, S. Berry, K. Broglio, 2014, Value in health regional issues.

18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2019, Liver Cancer.

Clinical features of hepatitis B virus genotype A in Japanese patients

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of hepatology.

Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Virology Journal.

Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of Gastroenterology.

Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of Gastroenterology.

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Drug design, development and therapy.

Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Hepatology communications.

Impact of hepatitis B core‐related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Alimentary pharmacology & therapeutics.

Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of Gastroenterology.

Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of Gastroenterology.

Low hepatitis B virus core-related antigen is a predictor of absence in post-treatment recurrence of hepatocellular carcinoma during antiviral therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009 .

Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of Gastroenterology.

Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of Gastroenterology.

Pretreatment heterogeneous enhancement pattern of hepatocellular carcinoma can be new predictor for early response to lenvatinib

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2019 .

Viral Dynamics and Pharmacokinetics in Combined Interferon Alfa-2b and Ribavirin Therapy for Patients Infected with Hepatitis C Virus of Genotype 1b and High Pretreatment Viral Load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Intervirology.

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus–related liver cancer

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Hepatology.

Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of hepatology.

Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of Gastroenterology.

Favorable efficacy of long‐term lamivudine therapy in patients with chronic hepatitis B: An 8‐year follow‐up study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Journal of medical virology.

Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of gastroenterology and hepatology.

Benefit of Lamivudine Therapy and Factors Associated with Clinical Outcome in Spontaneous Severe Acute Exacerbation of Chronic Hepatitis B Virus Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Intervirology.

YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of medical virology.

Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long‐term lamivudine therapy for hepatitis B e antigen‐positive chronic hepatitis B

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of medical virology.

Virological and biochemical relapse according to YMDD motif mutant type during long‐term lamivudine monotherapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of medical virology.

Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, American Journal of Gastroenterology.

Changes of laparoscopic histological findings in three cases of chronic hepatitis-B treated with Lamivudine.

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998 .

Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2019, Journal of Gastrointestinal Surgery.

Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma

Yoshiyuki Suzuki, K. Ikeda, M. Kobayashi, 2009, Liver international : official journal of the International Association for the Study of the Liver.

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Kenji Ikeda, Derek Y. Chiang, Goro Watanabe, 2008, The New England journal of medicine.

Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Liver Cancer.

Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Liver international : official journal of the International Association for the Study of the Liver.

Diagnosis of hepatocellular carcinoma by concanavalin a affinity electrophoresis of serum alpha‐fetoprotein

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1995, Cancer.

Highly sensitive AFP‐L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre‐ and postoperatively

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998, Hepatology.

Adefovir Dipivoxil for Treatment of Breakthrough Hepatitis Caused by Lamivudine-Resistant Mutants of Hepatitis B Virus

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Intervirology.

Clinical and virological features of non‐breakthrough and severe exacerbation due to lamivudine‐resistant hepatitis B virus mutants

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

HLA‐DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Liver international : official journal of the International Association for the Study of the Liver.

HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of medical virology.

Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, The American journal of medicine.

Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

Changes in viral loads of lamivudine‐resistant mutants during entecavir therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Virology Journal.

Development of HCC in patients receiving adefovir dipivoxil for lamivudine‐resistant hepatitis B virus mutants

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of entecavir treatment for lamivudine‐resistant hepatitis B over 3 years: Histological improvement or entecavir resistance?

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of gastroenterology and hepatology.

Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of Gastroenterology.

Clinical and virological effects of long‐term (over 5 years) lamivudine therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of Gastroenterology.

A Pilot Study of Thymosin α1 Therapy for Chronic Hepatitis B Patients

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003 .

A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Internal medicine.

Prevention of Disease Progression with Anti-Inflammatory Therapy in Patients with HCV-Related Cirrhosis: A Markov Model

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Oncology.

Necessities of interferon therapy in elderly patients with chronic hepatitis C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, The American journal of medicine.

Long‐term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of gastroenterology and hepatology.

Precore Wild-Type Hepatitis B Virus with G1896 in the Resolution of Persistent Hepatitis B Virus Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Intervirology.

Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Efficacy of switching to entecavir monotherapy in Japanese lamivudine‐pretreated patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of gastroenterology and hepatology.

Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology.

Diagnostic Problems Caused by HBsAg Mutants – A Consensus Report of an Expert Meeting

P. Coursaget, Yoshiyuki Suzuki, O. Yokosuka, 2004, Intervirology.

Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Intervirology.

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long‐term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, Hepatology.

Relationship between Five-Year Histological Outcome and Serial Changes in Serum Alanine Aminotransferase in Patients with Biochemical and Virological Relapse after Interferon Treatment for Chronic Hepatitis C

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Intervirology.

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of Gastroenterology.

Wild‐type precore and core promoter sequences in patients with acute self‐limited or chronic hepatitis B

A. Tsubota, Y. Suzuki, M. Kobayashi, 2004, Scandinavian journal of gastroenterology.

Increase of rtA181T mutant strains during entecavir therapy for a patient with chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010 .

Long‐term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide‐naïve chronic hepatitis B patients

Y. Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of viral hepatitis.

Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of Gastroenterology.

Randomized, controlled trial of natural interferon-α therapy for e-antigen-positive chronic hepatitis B patients

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002 .

Randomized, controlled trial of natural interferon-alpha therapy for e-antigen-positive chronic hepatitis B patients.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Hepatology research : the official journal of the Japan Society of Hepatology.

Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Long-Term Presence of HBV in the Sera of Chronic Hepatitis B Patients with HBsAg Seroclearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Intervirology.

Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, The American journal of medicine.

Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Journal of medical virology.

Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of Gastroenterology.

Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of medical virology.

Long-Term Clinical Remission Induced by Corticosteroid Withdrawal Therapy (CSWT) in Patients with Chronic Hepatitis B Infection: A Prospective Randomized Controlled Trial—CSWT with and Without Follow-Up Interferon-α Therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Digestive Diseases and Sciences.

Hepatitis G virus infection after blood transfusion in patients with chronic liver disease treated surgically for hepatocellular carcinoma

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1997 .

Extending Combination Therapy with Peginterferon plus Ribavirin for Genotype 2 Chronic Hepatitis C Virological Responders: A Pilot Study of 7 Cases

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Intervirology.

Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Internal medicine.

Efficacy in Patients with Dose Reduction in Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Intervirology.

Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2004, Journal of Gastroenterology.

Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

Prevalence of TT virus before and after blood transfusion in patients with chronic liver disease treated surgically for hepatocellular carcinoma

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, Journal of gastroenterology and hepatology.

Change of hepatitis B virus genotypes in acute and chronic infections in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

Long-term clinical remission induced by corticosteroid withdrawal therapy (CSWT) in patients with chronic hepatitis B infection: a prospective randomized controlled trial--CSWT with and without follow-up interferon-alpha therapy.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Digestive diseases and sciences.

The long term efficacy of glycyrrhizin in chronic hepatitis C patients

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1997, Cancer.

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.

A. Subramanian, S. Yamada, Bin Zhang, 2016, Cancer cell.

Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma

K. Rajewsky, M. Karin, M. Heikenwalder, 2015, Nature Immunology.

Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Cancer.

Transcriptome Profiling of Archived Sectioned Formalin-Fixed Paraffin-Embedded (AS-FFPE) Tissue for Disease Classification

Jian-Bing Fan, Xintong Chen, Craig S. April, 2014, PloS one.

Predictive factors in eradicating hepatitis C virus using a relatively small dose of interferon

K. Chayama, A. Tsubota, M. Kobayashi, 1998, Journal of gastroenterology and hepatology.

A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection

S. Friedman, J. Llovet, Y. Hoshida, 2015, Gut.

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

M. Kudo, S. Kaneko, J. Llovet, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An encapsulated bulky abdominal abscess due to amoeba

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Clinical Journal of Gastroenterology.

Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2020, Liver Cancer.

Recurrence Rate and Prognosis of Patients with Hepatocellular Carcinoma That Developed after Elimination of Hepatitis C Virus RNA by Interferon Therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Oncology.

Effectiveness of combination therapy of splenectomy and long‐term interferon in patients with hepatitis C virus‐related cirrhosis and thrombocytopenia

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma

K. Rajewsky, M. Karin, M. Heikenwalder, 2015, Nature Immunology.

Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, BMC Gastroenterology.

Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2021, Annals of Surgical Oncology.

Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2020, Oncology.

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib

J. Shindoh, Yoshiyuki Suzuki, Y. Eguchi, 2020, Internal medicine.

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

M. Kudo, N. Izumi, Y. Inaba, 2019, Journal of Gastroenterology.

Usefulness of HCV-RNA counts by the method of HCV-bDNA probe in interferon retreatment for patients with HCV-RNA positive chronic hepatitis C

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1995 .

Natural history of compensated cirrhosis in the Child‐Pugh class a compared between 490 patients with hepatitis C and 167 with B virus infections

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN‐resistant cases with hepatocyte steatosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Journal of medical virology.

Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of medical virology.

Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology.

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Internal medicine.

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Internal medicine.

Significance of Serum Ribavirin Concentration in Combination Therapy of Interferon and Ribavirin for Chronic Hepatitis C

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Intervirology.

Interferon Therapy for 2 Years or Longer Reduces the Incidence of Hepatocarcinogenesis in Patients with Chronic Hepatitis C Viral Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Intervirology.

Sustained Negativity for HCV-RNA over 24 or More Months by Long-Term Interferon Therapy Correlates with Eradication of HCV in Patients with Hepatitis C Virus Genotype 1b and High Viral Load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Intervirology.

Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Randomized controlled clinical trial of lymphoblastoid interferon-α for chronic hepatitis C

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001 .

Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology.

Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of hepatology.

Typing six major hepatitis C virus genotypes by polymerase chain reaction using primers derived from nucleotide sequences of the NS5 region

K. Chayama, H. Handa, M. Kobayashi, 1996 .

Biochemical and histological features of hepatitis G virus infection

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998, Journal of gastroenterology and hepatology.

Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of medical virology.

Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Hepatology.

Association of amino acid sequence in the PKR‐eIF2 phosphorylation homology domain and response to interferon therapy

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Hepatology.

Influence of amino‐acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin Treatment

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2012, Intervirology.

Risk factors of hepatitis C virus‐related liver cirrhosis in young adults: Positive family history of liver disease and transporter associated with antigen processing 2 (TAP2) *0201 Allele

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of medical virology.

Efficacy and safety in sitagliptin therapy for diabetes complicated by non‐alcoholic fatty liver disease

Yoshiyuki Suzuki, H. Sone, M. Kobayashi, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis.

J. Marrero, T. Yokoo, Quanzhen Li, 2021, Med.

Vaginal Variceal Hemorrhage in a Patient With Primary Biliary Cirrhosis: A Case Successfully Treated by Balloon-Occluded Retrograde Transvenous Obliteration

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, American Journal of Gastroenterology.

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Circulating microRNA‐122 levels are important predictor of hepatitis B virus surface antigen seroclearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2020, Liver Cancer.

Transcatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma (TACTICS-L) in Japan: Final analysis.

M. Kudo, K. Ueshima, H. Koga, 2022, Journal of Clinical Oncology.

High serum des‐gamma‐carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Cancer.

The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real‐life settings

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2011, Hepatology.

Long‐term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus‐related liver cirrhosis after interferon‐based therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Optimal management of patients with hepatocellular carcinoma treated with lenvatinib

S. Kaneko, M. Ikeda, M. Kobayashi, 2018, Expert opinion on drug safety.

Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Oncology.

Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Digestive Diseases and Sciences.

Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Journal of medical virology.

Incidence of the appearance of the red color sign on esophageal varices and its predictive factors: long-term observations of 359 patients with cirrhosis

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of Gastroenterology.

Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT

M. Kudo, R. Finn, F. Piscaglia, 2021, Journal of Gastroenterology.

Molecular signature predictive of long-term liver fibrosis progression to inform anti-fibrotic drug development

G. Klintmalm, S. Friedman, J. Marrero, 2021, Gastroenterology.

A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration

M. Mahajan, S. Friedman, Xintong Chen, 2014, Gut.

Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2020, Internal medicine.

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Internal medicine.

hepatocarcinogenesis following eradication of HCV RNA

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015 .

Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Internal medicine.

Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

Anticarcinogenic Impact of Interferon on Patients with Chronic Hepatitis C: A Large-Scale Long-Term Study in a Single Center

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2020, Clinical Journal of Gastroenterology.

A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117.

M. Kudo, N. Kato, M. Ikeda, 2020 .

Detection of TERT promoter mutation in serum cell‐free DNA using wild‐type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Journal of medical virology.

Difference in malignancies of chronic liver disease due to non‐alcoholic fatty liver disease or hepatitis C in Japanese elderly patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Evaluation of long‐term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Association of HLA-DR14 with the Treatment Response in Japanese Patients with Autoimmune Hepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Digestive Diseases and Sciences.

An Open Pilot Study Exploring the Efficacy of Fluvastatin, Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Genotype 1b in High Viral Loads

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

Primary liver carcinoma with sarcomatous changes: Analysis of 10 cases

F. Kondo, Yoshiyuki Suzuki, K. Kinowaki, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Fulminant Hepatitis due to de novo Hepatitis B after Cord Blood Transplantation Rescued by Medical Treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Internal medicine.

Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long‐term other nucleotide analog treatment in patients with chronic hepatitis B

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Gut and liver.

Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Japanese journal of clinical oncology.

Previous Chemoembolization Response after Transcatheter Arterial Chemoembolization (TACE) Can Predict the Anti-Tumor Effect of Subsequent TACE with Miriplatin in Patients with Recurrent Hepatocellular Carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Oncology.

Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

Effect of arterial administration of a high molecular weight anti-tumor agent, styrene maleic acid neocarzinostatin, for multiple small liver cancer—A pilot study

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1997, Journal of Gastroenterology.

Effect of arterial administration of a high-molecular weight antitumor agent, styrene maleic acid neocarzinostatin, in embolization-resistant liver cancer

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, International Journal of Clinical Oncology.

Usefulness and limitations of balloon‐occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Potential of a no‐touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis

T. Schiano, Y. Hoshida, S. Thung, 2020, The American journal of surgical pathology.

Microvascular Invasion and a Size Cutoff Value of 2 cm Predict Long-Term Oncological Outcome in Multiple Hepatocellular Carcinoma: Reappraisal of the American Joint Committee on Cancer Staging System and Validation Using the Surveillance, Epidemiology, and End-Results Database

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2019, Liver Cancer.

Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection

A. Tsubota, Y. Suzuki, M. Kobayashi, 2004, Journal of viral hepatitis.

Platelet-Albumin Score as a Sensitive Measure for Surgical Risk Prediction and Survival Outcomes of Patients with Hepatocellular Carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2018, Journal of Gastrointestinal Surgery.

Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle for hepatocellular carcinoma

Kenji Ikeda, Tetsuya Hosaka, Miharu Hirakawa, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma – direct ablative effects and a long‐term outcome

K. Ikeda, M. Kobayashi, H. Kumada, 2007, Liver international : official journal of the International Association for the Study of the Liver.

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan

M. Kudo, S. Ikeda, S. Kaneko, 2019, Journal of Gastroenterology.

Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, The American Journal of Gastroenterology.

A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).

M. Kudo, S. Kaneko, J. Llovet, 2020 .

Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2022, Hepatology International.

Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon α

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, Journal of Gastroenterology.

Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial.

M. Kudo, S. Ikeda, S. Kaneko, 2021, Value in health regional issues.

A randomized, double-blind, controlled trial of natural interferon-β therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1996, Journal of Gastroenterology.

Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Clinicopathological assessment of steatohepatitic hepatocellular carcinoma.

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2021, Clinics and research in hepatology and gastroenterology.

Efficacy and anticarcinogenic activity of interferon for hepatitis C virus‐related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Two cases receiving retreatment with 12 weeks of glecaprevir and pibrentasvir for HCV genotype 2 infection who failed prior glecaprevir and pibrentasvir therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Kanzo.

Hepatic fat quantification using the two‐point Dixon method and fat color maps based on non‐alcoholic fatty liver disease activity score

T. Miyati, T. Fujii, M. Kobayashi, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameter.

Yoshiyuki Suzuki, M. Hashimoto, G. Watanabe, 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

Stepwise Hook Extension Technique for Radiofrequency Ablation Therapy of Hepatocellular Carcinoma

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Oncology.

Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, BMC Gastroenterology.

Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology Research.

Randomized Controlled Trial Comparing the Efficacy of Impedance Control and Temperature Control of Radiofrequency Interstitial Thermal Ablation for Treating Small Hepatocellular Carcinoma

Kenji Ikeda, Tetsuya Hosaka, Masahiro Kobayashi, 2015, Oncology.

Effect of early antiviral agent therapy (NS3 and NS5A inhibitors) in chronic hepatitis C null responders

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011 .

Successful control of ruptured hepatocellular carcinoma with radiofrequency ablation

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Cholangiolocellular Carcinoma in a Young Patient Who Showed Sustained Virological Response after Treatment for Hepatitis C Virus Infection

F. Kondo, Yoshiyuki Suzuki, K. Kinowaki, 2017, Internal medicine.

New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Internal medicine.

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients.

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998, Journal of hepatology.

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity–determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1997, Hepatology.

Disease-Free Interval and Tumor Stage Complementarily Predict the Biological Behavior of Recurrent Hepatocellular Carcinoma

J. Shindoh, M. Hashimoto, M. Kobayashi, 2023, Annals of Surgical Oncology.

The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Internal medicine.

Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trial

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients.

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, European journal of gastroenterology & hepatology.

SUCCESSFUL HEMOSTASIS WITH OCTREOTIDE FOR BLEEDING FROM ULCERS DEVELOPING AFTER ENDOSCOPIC VARICEAL LIGATION ; REPORT OF TWO CASES

K. Chayama, M. Kobayashi, K. Ikeda, 1997 .

New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Hepatology International.

Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology International.

Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma

Yoshiyuki Suzuki, K. Ikeda, M. Kobayashi, 2009, Liver international : official journal of the International Association for the Study of the Liver.

A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration

M. Mahajan, S. Friedman, Xintong Chen, 2014, Gut.

Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Journal of Gastroenterology.

Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Transcatheter Arterial Chemotherapy with Miriplatin for Hepatocellular Carcinoma Patients with Chronic Renal Failure: Report of Three Cases

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Gut and liver.

CASE REPORT: Interferon-α for Reinfection with Hepatitis C Virus in Two Patients with Chronic Hepatitis C Who Had Responded to Previous Therapies

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Digestive Diseases and Sciences.

C型慢性肝炎に対するIFN-α及びIFN-βのコンビネーション療法の効果

A. Tsubota, M. Kobayashi, I. Koida, 1997 .

TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Oncology.

The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of hepatology.

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP‐424), pegylated interferon and ribavirin for 12 weeks

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology Research.

Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2011, Intervirology.

New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of hepatology.

Platelet-Albumin Score as a Sensitive Measure for Surgical Risk Prediction and Survival Outcomes of Patients with Hepatocellular Carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2018, Journal of Gastrointestinal Surgery.